On May 30, 2017 Bristol Myers-Squibb (BMS) announced two separate collaborations with its PD-1 immune checkpoint inhibitor, Opdivo (nivolumab). The separate deals involve Array BioPharma and Advaxis, the company announced in separate statements.
BMS entered into a clinical research collaOriginal Article
